![Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420397969-gr1.jpg)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
![Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/c9bf4572-ff4d-40de-ad3a-92b1ccce359d/gr3_lrg.gif)
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
![ALTA-3 trial design. Phase III trial comparing brigatinib and alectinib... | Download Scientific Diagram ALTA-3 trial design. Phase III trial comparing brigatinib and alectinib... | Download Scientific Diagram](https://www.researchgate.net/publication/354097629/figure/fig1/AS:1060317601746946@1629810824516/ALTA-3-trial-design-Phase-III-trial-comparing-brigatinib-and-alectinib-in-patients-with.png)
ALTA-3 trial design. Phase III trial comparing brigatinib and alectinib... | Download Scientific Diagram
CONVERT trial<br />Concurrent ONce-daily VErsus twice-daily RadioTherapy: A 2-arm randomised controlled trial of concurre
![PDF] Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study | Semantic Scholar PDF] Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3de15f90be53db01f657e998e8661910b7f9529c/5-Figure2-1.png)
PDF] Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study | Semantic Scholar
![Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/2099391090/2079187537/gr1.gif)
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
![Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0169500219307500-gr1.jpg)
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect
![Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer - ScienceDirect Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S205970292200148X-gr1.jpg)
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer - ScienceDirect
![Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/a2594401-024e-4f1d-bd08-a5e72e26e264/gr2_lrg.jpg)
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
![Jacob Plieth on X: "Alectinib vs Xalkori, ALEX study, via Dr Alice Shaw $RHHBY $NVS $PFE #ASCO17 https://t.co/FTTRKXBv8F" / X Jacob Plieth on X: "Alectinib vs Xalkori, ALEX study, via Dr Alice Shaw $RHHBY $NVS $PFE #ASCO17 https://t.co/FTTRKXBv8F" / X](https://pbs.twimg.com/media/DBj7SWYWAAQvawg.jpg:large)
Jacob Plieth on X: "Alectinib vs Xalkori, ALEX study, via Dr Alice Shaw $RHHBY $NVS $PFE #ASCO17 https://t.co/FTTRKXBv8F" / X
![Giannis Mountzios on X: "#brigatinib beating straight ahead #crizotinib in terms of PFS challenging #alectinib data from ALEX trial in ALK+ lung cancer with impressive intracranial response #LCSM #wclc2018 https://t.co/GvXL7zDD40" / X Giannis Mountzios on X: "#brigatinib beating straight ahead #crizotinib in terms of PFS challenging #alectinib data from ALEX trial in ALK+ lung cancer with impressive intracranial response #LCSM #wclc2018 https://t.co/GvXL7zDD40" / X](https://pbs.twimg.com/media/Dn8RUjYU8AA0S_E.jpg)
Giannis Mountzios on X: "#brigatinib beating straight ahead #crizotinib in terms of PFS challenging #alectinib data from ALEX trial in ALK+ lung cancer with impressive intracranial response #LCSM #wclc2018 https://t.co/GvXL7zDD40" / X
![Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study - Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study -](https://ars.els-cdn.com/content/image/1-s2.0-S1556086419302102-gr1.jpg)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study -
![Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S016950021830343X-gr1.jpg)
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect
![Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China - Su - 2023 - International Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China - Su - 2023 - International](https://onlinelibrary.wiley.com/cms/asset/d6e24eaf-c183-490d-bc0b-37fc2654a19a/ijc34123-toc-0001-m.jpg)
Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China - Su - 2023 - International
![Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence - Wang - 2022 - Cancer Medicine - Wiley Online Library Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence - Wang - 2022 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/61cf4254-682c-428e-a7a8-d7432f130c2a/cam44834-fig-0001-m.jpg)
Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence - Wang - 2022 - Cancer Medicine - Wiley Online Library
![Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420397969-gr2.jpg)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
![VIRTUAL] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor na&#239;ve ALK-positive non-small cell lung cancer (ALK+ NSCLC). VIRTUAL] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor na&#239;ve ALK-positive non-small cell lung cancer (ALK+ NSCLC).](https://pbs.twimg.com/media/E3DC6JqWEAUJeMz.jpg)
VIRTUAL] Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor na&#239;ve ALK-positive non-small cell lung cancer (ALK+ NSCLC).
![Debates in Treatment Sequencing in ALK-Rearranged NSCLC: Weighing Therapeutic Benefit Versus Troubling Toxicities Debates in Treatment Sequencing in ALK-Rearranged NSCLC: Weighing Therapeutic Benefit Versus Troubling Toxicities](https://dailynews.ascopubs.org/do/10.1200/ADN.22.201149/full/dn22_cc_villaruz_table-1666189634821.png)
Debates in Treatment Sequencing in ALK-Rearranged NSCLC: Weighing Therapeutic Benefit Versus Troubling Toxicities
![Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology](https://memoinoncology.com/wp-content/uploads/2020/02/82498.gif)